open access

Vol 65, No 12 (2007)
Other
Published online: 2007-12-21
Submitted: 2012-12-28
Get Citation


Original article
Sudden cardiac death risk factors in patients with heart failure treated with carvedilol

Jadwiga Nessler, Bohdan Nessler, Mariusz Kitliński, Anna Libionka, Aleksander Kubinyi, Ewa Konduracka, Wiesława Piwowarska
Kardiol Pol 2007;65(12):1417-1422.

open access

Vol 65, No 12 (2007)
Other
Published online: 2007-12-21
Submitted: 2012-12-28

Abstract


Background:

Chronic heart failure (CHF) is associated with a high risk of sudden cardiac death (SCD). Most frequently SCD occurs in patients with NYHA class II and III.
Aim:

To evaluate the influence of prolonged carvedilol therapy on SCD risk in CHF patients.
Methods:

The study included 86 patients (81 men and 5 women) aged 56.8±9.19 (35-70) years with CHF in NYHA class II and III receiving an ACE inhibitor and diuretics but not beta-blockers. At baseline and after 12 months of carvedilol therapy the following risk factors for SCD were analysed: in angiography – occluded infarct-related artery; in echocardiography – left ventricular ejection fraction (LVEF) 140 ml; in ECG at rest – sinus heart rate (HRs) >75/min, sustained atrial fibrillation, increased QTc; in 24-hour ECG recording – complex arrhythmia, blunted heart rate variability (SDNN 114 ms. The analysis of SCD risk factors in basic examination in patients who suddenly died was also performed.
Results:

During one-year carvedilol therapy heart transplantation was performed in 2 patients; 5 patients died. At 12 months the following risk factors for SCD were significantly changed: HRs >75/min (50 vs. 16 patients, p=0.006), LVEF

Abstract


Background:

Chronic heart failure (CHF) is associated with a high risk of sudden cardiac death (SCD). Most frequently SCD occurs in patients with NYHA class II and III.
Aim:

To evaluate the influence of prolonged carvedilol therapy on SCD risk in CHF patients.
Methods:

The study included 86 patients (81 men and 5 women) aged 56.8±9.19 (35-70) years with CHF in NYHA class II and III receiving an ACE inhibitor and diuretics but not beta-blockers. At baseline and after 12 months of carvedilol therapy the following risk factors for SCD were analysed: in angiography – occluded infarct-related artery; in echocardiography – left ventricular ejection fraction (LVEF) 140 ml; in ECG at rest – sinus heart rate (HRs) >75/min, sustained atrial fibrillation, increased QTc; in 24-hour ECG recording – complex arrhythmia, blunted heart rate variability (SDNN 114 ms. The analysis of SCD risk factors in basic examination in patients who suddenly died was also performed.
Results:

During one-year carvedilol therapy heart transplantation was performed in 2 patients; 5 patients died. At 12 months the following risk factors for SCD were significantly changed: HRs >75/min (50 vs. 16 patients, p=0.006), LVEF
Get Citation

Keywords

sudden cardiac death; heart failure; carvedilol; risk factors; heart rate; heart rate variability; heart rate turbulence; ejection fraction; late potentials

About this article
Title


Original article
Sudden cardiac death risk factors in patients with heart failure treated with carvedilol

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 65, No 12 (2007)

Pages

1417-1422

Published online

2007-12-21

Bibliographic record

Kardiol Pol 2007;65(12):1417-1422.

Keywords

sudden cardiac death
heart failure
carvedilol
risk factors
heart rate
heart rate variability
heart rate turbulence
ejection fraction
late potentials

Authors

Jadwiga Nessler
Bohdan Nessler
Mariusz Kitliński
Anna Libionka
Aleksander Kubinyi
Ewa Konduracka
Wiesława Piwowarska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl